535
edits
Changes
no edit summary
!Sample type
!LOD*** (H1N1)
TCID50/mL
|-
|Abbott<ref name="Arti18">Abbott RIDT Product Information, Abbott, https://www.globalpointofcare.abbott/nl/product-details/binaxnow-influenza-a-and-b.html</ref>
|Binax Now Influenza A & B Card 2
|Yes
|DIGIVAL
|70-89%<ref name="Arti18">Sensitivity and Specificity Abbott RIDT, Abbott, https://www.globalpointofcare.abbott/nl/product-details/binaxnow-influenza-a-and-b.html</ref>|90-99%<ref name="Arti18">Sensitivity and Specificity Abbott RIDT, Abbott, https://www.globalpointofcare.abbott/nl/product-details/binaxnow-influenza-a-and-b.html</ref>
|NPS, NS direct
|n/a
|-
|apDiaBecton Dickinson & Co.<ref name=”[28]”"Arti19">apDia Adalimumab ELISA (2016)Becton Dickinson & Co. RIDT Product Information, Becton Dickinson & Co. Leaflet ''apDia Adalimumab ELISA, https://www.'' apDiabd.com/en-us/offerings/capabilities/microbiology-solutions/point-of-care-testing/veritor-system</ref>|710201BD Veritor™ Flu A + B|Yes|BD veritor Reader|apDia Adalimumab ELISA82%|10 μL98%|NPS, NS direct|03.5-12 µg/mL3*10<br /sup>2.0- 48 µg/mL|1:99<br /sup>1:399|Intra-assay: CV 5.0*10< 10.1%sup>3<br /sup>Inter-assay: CV< 14.2%|1 hour 40 min.
|-
|Theradiag<ref name=”[29]”>LTA002 LISA-TRACKER Adalimumab (2017). Leaflet ''LTA002 LISA-TRACKER Adalimumab''. Theradiag.</ref>
